Stock Financial Ratios, Dividends, Split History

GPT / Gramercy Property Trust Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,397.48
Enterprise Value ($M)4,358.96
Book Value ($M)3,138.58
Book Value / Share19.52
Price / Book1.41
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 150,679,909
Common Shares Outstanding 160,782,974
Common Stock Shares Outstanding 160,686,822
Preferred Stock Shares Outstanding 3,500,000
Weighted Average Number Of Shares Outstanding Basic 150,660,964
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.02
Return on Equity (ROE)0.03
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Other Real Estate Revenue0.00
Revenue From Discontinued Operations0.00
Real Estate Revenue Net0.00
Reimbursement Revenue83,919,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Management Fees Revenue10,756,000.00
Net Income86.08
Earnings Per Share Diluted0.52
Earnings Per Share Basic And Diluted0.00
Earnings Per Share Basic0.52
Cash Flow Statement (mra) ($M)
Cash From Operations290.32
Cash from Investing-824.46
Cash from Financing-824.46
Identifiers and Descriptors
Central Index Key (CIK)1297587
Related CUSIPS
157842105 157842905 157842955

Split History

Stock splits are used by Gramercy Property Trust Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Industrial REITs Continue To Outperform, But Dollar Movement Could Hurt

2018-06-27 seekingalpha
Industrial REITs have outperformed other real estate asset classes, and with a booming economy and growing demand, the trend will likely continue.

Jane's May Dividend Income Tracker - Retirement Accounts

2018-06-19 seekingalpha
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57. (358-0)

SA Interview: Investing In REITs With Robert Ruggirello, CFA

2018-06-10 seekingalpha
Robert Ruggirello, CFA is the Managing Director of Brave Eagle Wealth Management, a NY-based Registered Investment Advisor. (19-0)

Good Things Are In Store For STORE Capital

2018-06-07 seekingalpha
In a recent Framework Investing Office Hour session, I spoke with one of Framework's members - hedge fund alum and New York City-based institutional investor, Robert Ruggirello, CFA - about a triple-net lease Real Estate Investment Trust called STORE Capital (NYSE:STOR). Robert's investment style was influenced by the work of the CIO of Yale College's Endowment, David Swenson, who suggests that a significant proportion of an investor's portfolio should be allocated to real assets. (39-0)

Lexington May Be Down, But Certainly Not Out

2018-05-28 seekingalpha
LXP’s dividend is safe, but don’t expect to see a lot of growth this year or next. (43-0)

CUSIP: 385002100